Wall Street analysts predict that Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) will announce ($0.19) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Lexicon Pharmaceuticals’ earnings, with estimates ranging from ($0.23) to ($0.17). Lexicon Pharmaceuticals posted earnings of ($0.26) per share during the same quarter last year, which would suggest a positive year over year growth rate of 26.9%. The company is expected to announce its next earnings report on Thursday, November 7th.
According to Zacks, analysts expect that Lexicon Pharmaceuticals will report full year earnings of ($0.80) per share for the current fiscal year, with EPS estimates ranging from ($0.89) to ($0.75). For the next financial year, analysts anticipate that the business will post earnings of ($0.66) per share, with EPS estimates ranging from ($1.23) to $0.07. Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that that provide coverage for Lexicon Pharmaceuticals.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($0.22) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by ($0.13). The company had revenue of $9.68 million for the quarter, compared to analysts’ expectations of $28.52 million. During the same quarter last year, the firm earned ($0.33) EPS. The business’s revenue for the quarter was down 29.9% compared to the same quarter last year.
In other news, Director Sam L. Barker acquired 24,000 shares of the stock in a transaction on Friday, August 2nd. The stock was bought at an average price of $1.18 per share, with a total value of $28,320.00. Following the completion of the transaction, the director now directly owns 40,187 shares of the company’s stock, valued at $47,420.66. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 6.40% of the stock is owned by company insiders.
A number of large investors have recently modified their holdings of LXRX. First Manhattan Co. acquired a new stake in Lexicon Pharmaceuticals in the first quarter valued at approximately $15,282,000. Pictet Asset Management Ltd. grew its position in Lexicon Pharmaceuticals by 42.6% in the first quarter. Pictet Asset Management Ltd. now owns 586,850 shares of the biopharmaceutical company’s stock valued at $3,263,000 after acquiring an additional 175,400 shares in the last quarter. Norges Bank acquired a new stake in Lexicon Pharmaceuticals in the fourth quarter valued at approximately $1,005,000. Fosun International Ltd grew its position in shares of Lexicon Pharmaceuticals by 79.9% during the first quarter. Fosun International Ltd now owns 181,000 shares of the biopharmaceutical company’s stock worth $952,000 after buying an additional 80,379 shares in the last quarter. Finally, Birchview Capital LP grew its position in shares of Lexicon Pharmaceuticals by 300.0% during the first quarter. Birchview Capital LP now owns 80,000 shares of the biopharmaceutical company’s stock worth $445,000 after buying an additional 60,000 shares in the last quarter. 98.28% of the stock is owned by institutional investors.
NASDAQ LXRX traded down $0.06 during mid-day trading on Monday, hitting $1.47. The company’s stock had a trading volume of 1,451,700 shares, compared to its average volume of 974,037. Lexicon Pharmaceuticals has a 52-week low of $1.13 and a 52-week high of $11.88. The company has a fifty day moving average price of $4.56. The stock has a market cap of $136.03 million, a price-to-earnings ratio of -1.29 and a beta of 0.77.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.
Featured Story: Buy Rating
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.